Longitudinal Urban Cohort Ageing Study

https://neurodegenerationresearch.eu/survey/longitudinal-urban-cohort-ageing-study-2/

Title (of co	hort
---------	-------	------

Longitudinal Urban Cohort Ageing Study

Acronym for cohort

LUCAS

Name of Principal Investigator - Title

Dr

Name of Principal Investigator - First name

Ulrike

Name of Principal Investigator - Last name

Dapp

Address of institution -Institution

ertinen-Haus, Centre for Geriatrics and Gerontology, Research Department

Address of institution - Street address

Sellhopsweg 18-22

Address of institution - City

Hamburg

Address of institution - Postcode

22459

Country

Germany

Website

www.geriatrie-forschung.de

Contact email

forschung@albertinen.de

Funding source

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Alzheimer's disease and other dementias Neurodegenerative disease in general

Q1b. When are studies on the above condition(s) expected to become possible?

Already Possible

Q2a. In a single sentence what is the stated aim of the cohort?

To enlighten the black box of the ageing process by establishing a longitudinal cohort making use of a randomised controlled trial (RCT) carried out in 2000 with over 3,300 independent senior citizens in the community of Hamburg. Information about pre-clinical markers for healthy ageing vs. the development of functional decline, has been collected multidimensionally in an interdisciplinary process since 2000.

Q2b. What distinguishes this cohort from other population cohorts? Q3a. i) Number of publications that involve use of your cohort to date

0

Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)

Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

60

Q4a. Study criteria: what is the age range of participants at recruitment? To:

98

Q4b. Study criteria: what are the inclusion criteria?

patients 60 + years in participating general practices (GP) in Hamburg in year 2000

Q4c. Study criteria: what are the exclusion criteria?

patients needing help in basic activities of daily life; patients obtaining nursing care according to the German long-term care insurance (Pflegeversicherung I-III); patients with cognitive impairment; patients with terminal disease and/or patients unable to understand German

Q5. What is the size of the cohort (i.e. how many participants have enrolled)?

1,000-5,000 participants

Q6a. Please describe what measures are used to characterise participants

multidimensional dataset using self-administered questionnaires in waves with whole cohort plus multidimensional assessments with randomly selected subgroups

Q6b. Are there additional measures for participants with a clinical disorder? Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

Yes

If yes please specify

functional status, nursing care (Pflegestufe), death

Q7. What is the study design (select all that apply)?

Longitudinal

Q8. Are your cases matched by

Age

Q9a. Does your study include a specialised subset of control participants?

Yes

Q9b. If your study includes a specialised subset of control participants please describe Q10a. i) Please enter the data collection start date

01/12/2000

Q10a. ii) Please enter the data collection end date Q10a. iii) Is data collection for this study

Data collection ongoing Data analysis ongoing

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

Yes - intend to apply for funding

Q11. Is data collected

Other please specify here

Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?

Q13a. Please give information on the format and availability of data stored in a database (1)

% available

Q13a. Please give information on the format and availability of data stored in a database (2)

% available

Q13a. Please give information on the format and availability of data stored in a database (3)

% available

Q13a. Please give information on the format and availability of data stored in a database (4)

% available

Other (please specify)

% available

Q13b. Please give information on the format and availability of data held as individual records (1)

% available

Q13b. Please give information on the format and availability of data held as individual records (2)

% available

Q13b. Please give information on the format and availability of data held as individual records (3)

% available

Q13b. Please give information on the format and availability of data held as individual records (4)

% available

Please specify language used

Q14a. Is data available to other groups?

Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?

Other criteria (only for LUCAS consortium partners until end of funding)

Q15. What data sharing policy is specified as a condition of use?

Data made publicly available after a specified time point

Q16a. Are tissues/samples/DNA available to other groups?

No

Q16b i) If yes, please describe below:

Q16b. ii) In what form are tissues/samples/DNA supplied?

Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

Q17. Is information on biological characteristics available to other groups?

No

Number of Patients % of total cohort

Types:

Population Cohorts

Member States:

Germany

Diseases:

Alzheimer's disease & other dementias, Neurodegenerative disease in general

Years:

2016

Database Categories:

N/A

Database Tags:

N/A